Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kol A Zarember

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Immunology|August 8, 2016
Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution ExperiencePaul L Feingold, Humair S Quadri, Seth M Steinberg, et al.
Infection and Immunity|August 19, 2015
Simultaneous Host-Pathogen Transcriptome Analysis during Granulibacter bethesdensis Infection of Neutrophils from Healthy Subjects and Patients with Chronic Granulomatous DiseaseDavid E Greenberg, Daniel E Sturdevant, Kimberly R Marshall-Batty, et al.
International Journal of Molecular Sciences|April 3, 2021
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid-Lipid A Glycolipid (Ko-Lipid A)Artur Muszyński, Kol A Zarember, Christian Heiss, et al.
Clinical Immunology (Orlando, Fla.)|June 19, 2013
B-cell activating factor (BAFF) is elevated in chronic granulomatous diseaseKabir Matharu, Kol A Zarember, Beatriz E Marciano, et al.
Inflammation|September 5, 2020
Low Plasma Gelsolin Concentrations in Chronic Granulomatous DiseaseJohn Audley, Emily F Gliniewicz, Kol A Zarember, et al.
The Journal of Allergy and Clinical Immunology|April 30, 2013
Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicismAmy P Hsu, Kathryn J Sowerwine, Monica G Lawrence, et al.
The Journal of Infectious Diseases|July 12, 2012
Serologic reactivity to the emerging pathogen Granulibacter bethesdensisDavid E Greenberg, Adam R Shoffner, Kimberly R Marshall-Batty, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 8, 2014
An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous diseaseRandall K Merling, Colin L Sweeney, Jessica Chu, et al.
Science Translational Medicine|January 13, 2017
CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous diseaseSuk See De Ravin, Linhong Li, Xiaolin Wu, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Immunology|August 8, 2016
Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution ExperiencePaul L Feingold, Humair S Quadri, Seth M Steinberg, et al.
Infection and Immunity|August 19, 2015
Simultaneous Host-Pathogen Transcriptome Analysis during Granulibacter bethesdensis Infection of Neutrophils from Healthy Subjects and Patients with Chronic Granulomatous DiseaseDavid E Greenberg, Daniel E Sturdevant, Kimberly R Marshall-Batty, et al.
International Journal of Molecular Sciences|April 3, 2021
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid-Lipid A Glycolipid (Ko-Lipid A)Artur Muszyński, Kol A Zarember, Christian Heiss, et al.
Clinical Immunology (Orlando, Fla.)|June 19, 2013
B-cell activating factor (BAFF) is elevated in chronic granulomatous diseaseKabir Matharu, Kol A Zarember, Beatriz E Marciano, et al.
Inflammation|September 5, 2020
Low Plasma Gelsolin Concentrations in Chronic Granulomatous DiseaseJohn Audley, Emily F Gliniewicz, Kol A Zarember, et al.
The Journal of Allergy and Clinical Immunology|April 30, 2013
Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicismAmy P Hsu, Kathryn J Sowerwine, Monica G Lawrence, et al.
The Journal of Infectious Diseases|July 12, 2012
Serologic reactivity to the emerging pathogen Granulibacter bethesdensisDavid E Greenberg, Adam R Shoffner, Kimberly R Marshall-Batty, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 8, 2014
An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous diseaseRandall K Merling, Colin L Sweeney, Jessica Chu, et al.
Science Translational Medicine|January 13, 2017
CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous diseaseSuk See De Ravin, Linhong Li, Xiaolin Wu, et al.
Pageof 5